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Objective: Factors responsible for the variability in outcomes after lower extremity vein bypass grafting (LEVBG) are
poorly understood. Recent evidence has suggested that a single nucleotide polymorphism (SNP) in the promoter region
of the p27Kip1 gene, a cell-cycle regulator, is associated with coronary in-stent restenosis. We hypothesized an association
with vein graft patency.
Methods: This was a retrospective genetic association study nested within a prospective cohort of 204 patients from three
referral centers undergoing LEVBG for claudication or critical ischemia. The main outcome measure was primary vein
graft patency.
Results: All patients were followed up for a minimum of 1 year with duplex graft surveillance (median follow-up, 893 days;
interquartile range, 539-1315). Genomic DNA was isolated and SNP analysis for the p27Kip1-838C>A variants was
performed. Allele frequencies were correlated with graft outcome using survival analysis and Cox proportional hazards
modeling. The p27Kip1-838C>A allele frequencies observed were CA, 53%; CC, 30%; and AA, 17%, satisfying
Hardy-Weinberg equilibrium. Race (P[ .025) and history of coronary artery disease (P[ .027) were different across the
genotypes; all other baseline variables were similar. Primary graft patency was greater among patients with the -838AA
genotype (75% AA vs 55% CA/CC at 3 years; P [ .029). In a Cox proportional hazards model including age, sex, race,
diabetes, critical limb ischemia, redo (vs primary) bypass, vein type, and baseline C-reactive protein level, the p27Kip1-838AA
genotype was signiﬁcantly associated with higher graft patency (hazard ratio for failure, 0.4; 95% conﬁdence interval, 0.17-
0.93). Genotype was also associated with early (0-1 month) changes in graft lumen diameter by ultrasound imaging.
Conclusions: These data suggest that the p27Kip1-838C>A SNP is associated with LEVBG patency and, together
with previous reports, underscore a central role for p27Kip1 in the generic response to vascular injury. (J Vasc Surg
2013;57:1179-85.)First described more than 60 years ago,1 autogenous
vein bypass grafting remains a key therapeutic option for
patients with extensive peripheral artery disease as well as
coronary artery disease. In the United States Medicare pop-
ulation, more than 100,000 lower extremity and 200,000
coronary bypass graft procedures are performed each year
for relief of ischemia.2,3 Although vein grafts in the lower
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or conﬂict of interest: none.de novo stenosis within the graft occurs in 30% to 50% of
patients within the ﬁrst several years, often necessitating
repeat intervention.4-8 Despite attention to vein harvesting
trauma, improved surgical techniques, modiﬁcation of con-
ventional atherosclerosis risk factors (eg, smoking cessation,
lipid-lowering drugs), and antithrombotic therapies, the in-
cidence of vein graft disease has not changed perceptibly
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graft remodeling and clinical outcomes among individual
patients.9
The prototypic response of blood vessels to mechanical
trauma, namely, the development of neointimal thickening,
may become clinically manifest as lumenal renarrowing after
angioplasty, stent placement, and bypass grafting. The acute
injury triggers a proliferative responsive in resident vascular
smooth muscle cells (VSMCs) and adventitial cells via cell-
cycle activation. Normally quiescent in the uninjured vessel,
VSMCs rapidly respond to local cytokine and growth factor
signals and are released from growth inhibition by coordi-
nated activity of cell cycle proteins.10 The cyclin-
dependent kinase (CDK) inhibitor p27Kip1 is a critical
gatekeeper of the G1-S checkpoint, blocking cell-cycle entry
by inhibiting CDK-cyclin interactions, speciﬁcally that
between cyclin E-CDK2 and cyclin D-CDK4.11 Numerous
lines of evidence suggest that p27Kip1 plays an important
role in the response to vascular injury and in atheroscle-
rosis.12-14
Recent studies have demonstrated the potential role of
genetic variability as a determinant of clinical outcomes in
patients with cardiovascular disease and after clinical inter-
ventions. Of interest, a single nucleotide polymorphism
(SNP) in the p27Kip1 gene (-838C>A; rs36228499) was
recently identiﬁed as a potential risk factor for myocardial
infarction.15 In a retrospective association study in two
Dutch cohorts of patients who had undergone percuta-
neous placement of bare-metal stents (BMS) in coronary
arteries, this single nucleotide polymorphism (SNP) was
identiﬁed as a strong predictor of in-stent restenosis.16
We hypothesized that genetic factors related to neointimal
disease in venous bypass grafts would be similar to those in
injured arteries and that variability in the p27Kip1 gene
would be associated with vein graft disease. Our ﬁndings
support a potentially central role for p27Kip1 as a global
determinant of cardiovascular intervention outcomes.
METHODS
Study design and cohorts. This was a retrospective
study designed to test the speciﬁc hypothesis that the
p27Kip1-838C>A SNP (rs36228499) is associated with
primary patency of lower extremity vein bypass grafts
(LEVBGs).
The primary cohort of 204 patients was derived from
a prospective study examining the relationship between
systemic inﬂammation and clinical outcomes after LEVBG
at three Boston hospitals (Brigham and Women’s Hospital,
Beth Israel Deaconess Medical Center, Boston VA Medical
Center). This study was sponsored by the National Heart,
Lung and Blood Institute (HL 75771). The inclusion and
exclusion criteria of this cohort have been described else-
where.17,18 Brieﬂy, patients were eligible for enrollment if
they were undergoing primary or redo lower extremity
bypass surgery with autogenous vein for lifestyle-limiting
claudication or critical limb ischemia. Importantly, patients
were excluded if they had a recent pre-existing condition
likely to inﬂuence systemic inﬂammation, includingmyocardial infarction, stroke, major illness, or major opera-
tion#30 days of the bypass surgery, evidence of foot infec-
tion, or current use of immunosuppressant medications.
Patients were also excluded if any portion of the bypass
was constructed with nonautogenous material.
All patients provided written informed consent, and the
study protocol was approved by the respective Institutional
Review Boards (IRBs) at the participating sites. Patients
were enrolled between 2004 and 2007 and were followed
up for a minimum of 1 year (median follow-up, 32 months).
A preoperative blood sample was drawn on all study partic-
ipants, and aliquots of anticoagulated whole blood were
frozen at –80C. Of the 225 individuals enrolled in this
study, DNA samples were available for genotyping from
204, which are the subject of the analysis.
A second cohort of 51 patients examined in this study
was derived from two Seattle hospitals (University of Wash-
ington Medical Center and the VA Puget Sound Health
Care System). These individuals were enrolled in a series
of prospective, observational pilot studies examining the
associations between graft stenosis, platelet/monocyte
activity, and growth patterns of cells obtained from vein
grafts (Supplementary Table I).19,20 The studies were
approved by the IRBs at both institutions, and all patients
gave informed consent. Patients were excluded if they were
unable to give informed consent or to return for follow-up
examinations. Participants in the Seattle cohort were
recruited between 2004 and 2009. Patients were followed
up for a minimum of 12 months. Anticoagulated whole
blood was obtained at baseline and frozen at –80C.
Clinical assessments and end point deﬁnitions. All
patients in the Boston cohort were followed up by their
vascular surgeons for clinical and graft-related events at 1,
3, 6, 9, and 12 months, and every 6 months thereafter until
termination from the study. Study personnel recorded
clinical or graft-related events during the postoperative
visits, including rehospitalizations, major adverse cardio-
vascular events, amputations, graft revisions, or graft
occlusions. Under the study protocol, patients underwent
duplex ultrasound surveillance of their bypass grafts at each
visit at 1, 3, 6, 9, and 12 months, and thereafter at 6-month
intervals. For the Seattle cohort, the follow-up assessment
schedule included clinical and duplex ultrasound graft
examinations at 6 weeks and at 3, 6, and 12 months after
surgery. Primary and secondary graft patency were deﬁned
in accordance with accepted guidelines for reporting of
lower extremity revascularization.21
Genomic DNA and SNP analysis. Genomic DNA
was isolated from whole blood using a puriﬁcation kit and
the manufacturer’s suggested protocol (Wizard; Promega
Corp, Madison, Wisc). The p27Kip1-838C>A SNP was
genotyped by polymerase chain reaction using the follow-
ing primers: forward: TCCAGGTCCCGGCTTCCCGGt,
reverse: CCTGCTCTGGCTGGCCTCGGAG. Amismatch
creating a Taq1 site when -838C is present is shown in lower
case. Reactions were performed using a programmable ther-
mocycler (MJ Research, St. Bruno, Quebec, Canada), and
the reaction product was digested with Taq1 (10 hours at
Table I. Characteristics of Boston lower extremity vein
bypass (LEVB) graft cohort by the p27 Kip1-838 genotype
Variablea -838AA -838CA -838CC Pb
Patients 35 (17.2) 108 (52.9) 61 (29.9)
Age, years 67.3 6 12.1 66.8 6 67.5 67.8 6 9.95 .891
Male sex 26 (74.3) 81 (75.0) 40 (65.6) .402
Race
Caucasian 31 (88.6) 99 (91.7) 47 (77.1) .025
African
American
0 8 (7.4) 8 (13.1) .069
Hispanic 3 (8.6) 1 (0.93) 6 (9.8) .020
hsCRP >5 mg/L 14 (40.0) 36 (33.3) 24 (39.3) .650
CLI 20 (57.1) 62 (57.4) 37 (60.7) .908
Diabetes mellitus 19 (54.3) 53 (49.1) 35 (57.4) .567
CAD 14 (40.0) 56 (51.9) 41 (67.2) .027
Current tobacco
use
10 (28.6) 46 (42.6) 22 (36.1) .305
BMI, kg/m2 27.1 6 5.03 29.1 6 7.4 28.7 6 7.36 .325
Tissue loss 9 (25.7) 33 (30.6) 21 (34.4) .670
Redo LEVB 3 (8.6) 11 (10.2) 6 (9.8) .962
SSGSV conduit 32 (91.4) 91 (84.3) 46 (75.4) .114
Nonreversed
SSGSV
23 (65.7) 66 (61.1) 35 (57.4) .719
Infrapopliteal
target
17 (48.6) 47(43.5) 36 (59.0) .153
Statin use 30 (85.7) 89 (82.4) 47 (77.1) .532
Antiplatelet Rx 29 (82.9) 86 (79.6) 49 (80.3) .916
BMI, Body mass index; CAD, coronary artery disease; CLI, critical limb
ischemia; hsCRP, high-sensitivity C-reactive protein; SSGSV, single-segment
great saphenous vein.
aContinuous data re shown as mean6 standard deviation and categoric data
as number (%).
bc2 test.
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bromide staining.
Ultrasound imaging substudy. We prospectively
enrolled patients from one of the study sites (Brigham and
Women’s Hospital in Boston) in an IRB-approved imaging
substudy designed to examine remodeling patterns in vein
bypass conduits using high-resolution ultrasound imaging.
The methods for this substudy have been reported previ-
ously.18 In brief, after informed consent, participants
underwent serial ultrasound assessment of a deﬁned, regis-
tered 5-cm region of their bypass graft using B-mode,
M-mode, and Doppler modalities. The designation of the
region of interest of the conduit (index segment) was made
in the operating room and was speciﬁcally selected as
a straight, valveless vein segment $5 cm away from the
proximal anastomosis and in a superﬁcial location. Surgical
clips were placed as a reference, and the distance from the
proximal anastomosis was recorded for subsequent identiﬁ-
cation. The initial set of images was acquired in the operating
room after completion of the bypass graft and before wound
closure. Five high-resolution M-mode cross-sectional
images of the vein were recorded at each 1-cm interval
along the index segment using an ATL HDI 3000 ultra-
sound machine (Advanced Technology Laboratories,
Bothell, Wash) with a 10-MHz transducer and cardiac
gating. Lumen diameter was calculated as the mean of these
25 measurements. At postoperative visits, in addition to
standard Duplex graft surveillance, these patients had
detailed imaging acquisition of the index segment of the
conduit using the same protocol.
Statistical methods. Hardy-Weinberg equilibriumwas
ﬁrst evaluated among the full Boston cohort and then in the
subset who self-reported as white. There were no signiﬁcant
deviations from Hardy-Weinberg equilibrium (P > .20).
The primary analyses were performed using the larger
Boston cohort, with the Seattle cohort analyzed separately
as a conﬁrmatory population. Graft patency rates were
estimated by life-table analysis. Univariate associations
between genotype and graft outcomes were performed by
log-rank test. A Cox proportional hazards model was used
incorporating demographic (age, race, sex) variables and
other variables relevant to LEVBG outcomes, including
diabetes, critical limb ischemia as the indication, redo
bypass, and baseline high-sensitivity C-reactive protein level,
in addition to the p27 genotype. A value of P < .05 was
considered statistically signiﬁcant for all tests.
RESULTS
Characterization of the study population by p27
genotype. Characteristics of subjects in the Boston cohort
by p27Kip1-838C>A genotype are summarized in Table I
(see Supplementary Table II, online only, for the Seattle
cohort). Mean age was 70 years, 82% were white, and 45%
were women. Race (P ¼ .025) and history of coronary
artery disease (P ¼ .027) were different across the geno-
types; all other baseline variables including use of anti-
platelet and statin medications were similar between the
groups. There were no failures of genotyping for this SNP.The p27Kip1-838C>A allele frequencies observed were
CA, 53%; CC, 30%; and AA, 17% in the Boston cohort and
CA, 65%, CC 23%, and AA 12% in the Seattle cohort. Age,
race, and sex distributions for the Seattle cohort were
similar to that of the Boston cohort.
Clinical outcomes. For the Boston cohort, 78 patients
lost primary patency during follow-up. By life-table analysis,
the overall primary patency rate was 69%6 3% at 1 year and
60%6 4% at 3 years. Secondary patency was 85%6 3% and
82% 6 3% at 1 and 3 years respectively.
Early (30-day) event rates were not different by
genotype (Table II). Primary graft patency tended to be
associated with p27Kip1-838 genotype, with the patients
having the AA genotype demonstrating improved patency
(P ¼ .066 by log-rank test; Table II; Fig 1). Because the
observed pattern was consistent with a recessive model,
we combined the CA and CC groups for subsequent anal-
ysis. In this analysis, AA genotype was signiﬁcantly associ-
ated with primary graft patency (P ¼ .029 by log-rank
test; Fig 2).
In the Seattle cohort, a similar trend was observed in
primary patency by p27Kip1-838C>A genotype (83% AA
vs 60% CA/CC at 1 year; P ¼ .27 by c2; Supplementary
Table III, online only).
Multivariable model for primary graft patency.
A Cox proportional hazards model using the Boston cohort
Table II. Summary of clinical outcomes in Boston
cohort by p27Kip1-838 genotype
Variablea
AA,
No. (%)
CA,
No. (%)
CC,
No. (%) Pb
30-day
Graft failure 3 (8.6) 6 (5.6) 0 (0) .921
MACE 3 (8.6) 7 (6.5) 2 (3.3) .908
% (SEM) % (SEM) % (SEM)
Primary patency
1 year 81.0 (7.0) 67.5 (4.7) 62.1 (6.4) .066
3 years 76.5 (7.9) 58.2 (5.4) 51.2 (7.4) .066
Secondary patency
1 year 90.6 (5.1) 80.4 (4.3) 86.1 (8.6) .163
3 years 90.6 (5.1) 76.8 (4.6) 83.8 (5.0) .163
3-year outcome
Limb loss 91.0 (4.9) 95.0 (2.1) 96.5 (2.4) .721
Survival 74.9 (8.5) 74.9 (8.5) 83.5 (5.1) .903
MACE, Major adverse cardiovascular event, including death, myocardial
infarction, stroke; SEM, standard error of the mean.
aAll rates >30 days are by life-table analysis, shown as % (SEM); 30-day
event rates are raw proportion.
bUnivariate P-values by log-rank or logistic regression analysis.
Fig 1. Life-table plot shows primary lower extremity vein bypass
graft patency by p27 kip1-838 genotype for the 204 individuals in
the Boston cohort. Data are shown with the standard error of the
mean brackets.
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signiﬁcantly associated with primary graft patency (hazard
ratio for AA, 0.41; 95% conﬁdence interval, 0.18-0.97;
P ¼ .039), adjusting for age, race, diabetes, redo bypass,
indication (critical ischemia vs claudication), and baseline
high-sensitivity C-reactive protein (Table III). Analyses
restricted to the individuals who self-reported as white race
had very similar point estimates (hazard ratio for AA, 0.39;
95% conﬁdence interval, 0.16-0.99; P ¼ .048) including
adjustment for the same set of covariates.
Vein remodeling. We analyzed data from the imaging
substudy to look for associations between patterns of
vein remodeling after arterialization and the p27Kip1-838
genotype. There were 55 patients who participated in the
ultrasound substudy, had imaging data available from
the intraoperative and 1-month scans, and had been geno-
typed for the p27 SNP of interest. We found that individuals
with the homozygous CC genotype had signiﬁcantly less
early dilation (0-1 month) of the venous conduit (P ¼ .045
by analysis of variance; Fig 3). This association was
unchanged when restricted to the 45 white patients. Owing
to themodest size of the substudy cohort, we were unable to
deﬁne signiﬁcant associations between genotypes and later
remodeling changes or to conduct further multivariable
analysis across genotypes.
Comparison with other cohorts. Table IV summa-
rizes the genotype frequencies, prevalence of stenosis
(artery or graft), and point estimate effect size for the
Boston and Seattle vein graft cohorts compared with the
coronary BMS outcomes in the Dutch cohort reported by
van Tiel et al.16 Reﬂective of a largely white population in
the current study populations, likely enriched for European
descent, the genotype frequencies seen are broadly similar
across the North American and Dutch cohorts. The
protective AA genotype was present in 12% to 21% of thesepopulations. The strikingly similar estimates of a protec-
tive association between the AA genotype and target
vessel stenosis across the peripheral bypass and coronary
BMS studies suggest a fundamental association between
p27Kip1-838C>A genotype and the vascular injury res-
ponse in disparate vessels and circulatory beds.
DISCUSSION
To our knowledge, this report identiﬁes the ﬁrst poten-
tial geneticmarker for LEVBGoutcomes, a common SNP in
the promoter region (position -838) of the gene for the cell-
cycle inhibitor, p27Kip1. Patients homozygous for the minor
variant A allele, roughly one of six individuals in the study
population, experienced a 2.5-fold reduction in subsequent
vein graft failure. This association was independent of demo-
graphic and clinical risk factors even in a modest-sized pop-
ulation, which suggests it is likely robust. Moreover, the
magnitudeof the effectwas strikingly similar across two inde-
pendent vein graft cohorts, as well as a Dutch coronary BMS
population.Although these ﬁndings require further prospec-
tive validation, they suggest a potentially important global
marker of genetic variability in the vascular injury response.
The cell-cycle inhibitor p27Kip1 is known to play a critical
role in the regulation of vascular cell proliferation, with
complementary evidence fromboth animalmodels of disease
and human vascular lesions.10,13,22 After arterial injury,
increased p27Kip1 expression coincides with decreased cel-
lular proliferation by 5-bromo-2-deoxyuridine staining.12
Genetic studies in mice demonstrate a prominent inhibitory
role of p27Kip1 on atherogenesis and injury-induced neointi-
mal hyperplasia.23 In a rabbit vein graft model, local treat-
ment with rapamycin resulted in elevated levels of p27Kip1
that correlated directly with reduced proliferation and less
early intimal thickening.24
Current understanding of the adaptive process of vein
arterialization and its relationship to subsequent bypass graft
disease in humans remains quite incomplete. After
Fig 2. Life-table plot shows primary lower extremity vein bypass
graft patency by p27Kip-838 genotype, using a recessive model (AA
vs CA þ CC). Data are shown with the standard error of the mean.
Table III. Cox proportional hazards model for primary
graft patency
Variable HR (95% CI) Pa
Age 1.01 (0.99-1.03) .387
Non-white race 2.0 (1.12-3.60) .019
Diabetes 1.58 (0.95-2.62) .075
Critical limb ischemia 1.52 (0.86-2.69) .151
Re-do bypass 1.99 (1.03-3.84) .041
Baseline hs-CRP >5 mg/L 1.23 (0.77-2.16) .335
p27Kip1-838AA 0.41 (0.18-0.97) .039
CI, Conﬁdence interval; HR, hazard ratio; hs-CRP, high-sensitivity
C-reactive protein.
aThere is no corresponding footnote for “a” in Table III.
Fig 3. Percentage change (mean 6 standard deviation) is shown
in vein graft lumen diameter from baseline (intraoperative after
implantation) to 1 month, in a subset of 55 patients who took part
in a detailed ultrasound imaging substudy,18 by p27Kip1-838
genotype (P ¼ .045 by analysis of variance).
Table IV. Relative effects size of the AA genotype in
three different cohorts
Cohort No.
Overall
prevalence
of stenosis, %
Frequency
of -838AA
genotype, %
Point estimate
of effect size
Boston 202 34.8 17.2 .41 (HR)
Seattle 51 37.3 11.8 .30 (OR)
Netherlands16 598 18 21.2 .29 (HR)
HR, Hazard ratio, OR, odds ratio.
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structural remodeling in response to acutely elevated shear
and tensile forces, leading to some requisite wall thickening.
An integrated biomechanical/biochemical approach is
needed to explain the observed variability in this response,
both along the course of a given conduit and among indi-
vidual patients.25 Lumen caliber in the vein graft is deter-
mined by wall thickness and remodeling. We have
previously reported the time course and variability of vein
graft remodeling in the lower extremity, highlighting the
importance of early outward remodeling on subsequent clin-
ical outcomes.18,26 In our imaging substudy cohort, individ-
uals with the homozygous p27Kip1-838CC genotype had
notably inferior remodeling during the ﬁrst postoperative
month. These data, although preliminary, suggest that
genetic variability in p27Kip1may inﬂuence the early adaptive
dilation response in the arterialized vein. Because ultrasound
imaging is limited to lumen dimensions, we are not able to
discriminate changes inwall thickness or composition associ-
atedwith these ﬁndings.Graft failure is a complex phenotype
consisting of several factors, including remodeling, wall
thickness, and thrombosis. We postulate that the apparent
discrepancy between a dominant vs a recessive inﬂuence oftheA allele on early remodeling vs clinical patencymay reﬂect
these different components.
Interest in blocking cell cycle activation as a means of
reducing neointimal thickening in bypass grafts stems from
a large body of animal and in vitro studies. Of note, the
PRoject of Ex-Vivo vein graft ENgineering via Transfection
(PREVENT) clinical trials tested a molecular strategy of
cell-cycle inhibition via a transcription factor“decoy” (antag-
onist of E2F) in two large phase 3 trials (coronary andperiph-
eral), both of which were negative.27,28 The reasons for
failure of the test agent in these studies remain unclear;
however, variability in clinical outcomes across a range of
patient-level factors, including race and sex, was observed
in these largemulticenter studies. There are few prior reports
describing genetic association studies in vein bypass
outcomes,29-31 and none involving peripheral grafting.
Importantly, our study was not a broad exploratory investi-
gation of genetic associations but rather a hypothesis-based
JOURNAL OF VASCULAR SURGERY
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recent coronary studies.
One of the salient ﬁndings from this study is the striking
concordance in both prevalence and beneﬁcial association of
the p27Kip1-838C>A SNP across our two geographic
centers and one in Europe, and two distinct types of vascular
injury (stent in the coronary artery and vein bypass in
the leg). Although clearly requiring further larger-scale vali-
dation studies and expanding to larger numbers of nonwhite
individuals, these ﬁndings suggest that this marker may be of
unique clinical and biologic signiﬁcance. The initial report
from Gonzalez et al16 linking the p27Kip1-838C>A SNP
to an increased risk of myocardial infarction is also important
to consider because it appears contradictory in clinical terms.
We consider the hypothesis proposed by van Tiel et al,16 that
is the differential role of VSMC proliferation in maintaining
ﬁbrous cap integrity of native atherosclerosis lesions vs
promoting restenosis, as a logical explanation that requires
further study.
This investigation has a number of important limita-
tions, among which the modest size and limited diversity
of the study population is paramount. Nevertheless, this
limitation is counterbalanced by the considerable power
of long-term imaging surveillance of the bypass grafts in
these individuals, allowing for accurate assessment of the
timing and progression of vein graft lesions that is not
generally obtainable in coronary studies.
Second, we do not have evidence to directly link the
p27Kip1-838C>A SNP to expression of p27Kip1 within
tissue from the patients. Therefore we cannot discriminate
between association and causation in our ﬁndings. Of note,
van Tiel et al16 examined the potential functional signiﬁ-
cance of the p27Kip1-838C>A SNP using a recombinant
promoter-luciferase construct in human embryonic kidney
293 cells, demonstrating a large increase in promoter
activity with the -838A construct compared with the
-838C construct. In preliminary studies using these iden-
tical constructs (courtesy Carlie J. M. deVries), we have
conﬁrmed these relative ﬁndings in both human embryonic
kidney 293 cells and in primary cultured adventitial ﬁbro-
blasts from human saphenous vein (Supplementary Fig,
online only). However, more direct evidence linking tissue
expression to p27Kip1 genotype is needed to support the
hypothesis for causation.CONCLUSIONS
Failure rates of clinical interventions for the treatment of
peripheral arterial disease remain high, and the prediction
and prevention of such failures is a signiﬁcant unmet clinical
need. Our studies support the need for broader efforts to
identify the role of genetic variability in treatment outcomes,
whichmay lead to improvements in patient selection, surveil-
lance, and postinterventional therapies to reduce the burden
of restenosis. These ﬁndings highlight that such efforts
should consider common phenotypic patterns between
different types of interventions and vascular beds as well as
other related forms of mechanical and surgical trauma. Asone example, the p27Kip1-838C>A SNP is a commonly
encountered genetic variant that may help to explain some
of the unpredictable failure risk associated with therapeutic
cardiovascular interventions.
We acknowledge Carlie J. M. deVries (University of
Amsterdam) for providing primer sequences, variant p27
promoter constructs, and for scientiﬁc advice in the geno-
typing experiments. Diana Kim assisted with management
of the clinical database and blood samples for this project.
Genomic DNA extraction was performed by the University
of California, San Francisco, DNA Bank. Mark Caldwell
provided technical assistance with sample genotyping. We
also acknowledge participating surgeons from the Boston
and Seattle hospitals who enrolled patients in the respective
cohort studies used for this analysis, particularly Drs. Allen
D. Hamdan (Beth Israel Deaconess Medical Center,
Boston), Frank B. Pomposelli Jr (Beth Israel Deaconess
Medical Center, Boston), and Joseph D. Raffetto (Boston
VA Medical Center, Boston). Lihua Chen, PhD, assisted
with performance of the p27 promoter assays.AUTHOR CONTRIBUTIONS
Conception and design: MC, AC
Analysis and interpretation: MC, CO, MB, MC, KE, WG,
RK, RL, MS, AC
Data collection: MC, CO, RK
Writing the article: MC, CO, KE, WG, RK, RL, AC
Critical revision of the article: MC, CO, MB, MC, KE,
WG, RK, RL, MS, AC
Final approval of the article: MC, CO, MB, MC, KE, WG,
RK, RL, MS, AC
Statistical analysis: MC, CO, KE, WG, RK
Obtained funding: MC
Overall responsibility: MCREFERENCES
1. Kunlin J. Le traitement de l’artere obliterante par la greffe veineuse
[The treatment of arterial obstruction by vein grafting]. Arch Mal
Coeur Vx 1949:42.
2. Sachs T, Pomposelli F, Hamdan A, Wyers M, Schermerhorn M. Trends
in the national outcomes and costs for claudication and limb threat-
ening ischemia: angioplasty vs bypass graft. J Vasc Surg 2011;54:
1021-31.e1.
3. Riley RF, Don CW, Powell W, Maynard C, Dean LS. Trends in
coronary revascularization in the United States from 2001 to 2009:
recent declines in percutaneous coronary intervention volumes. Circ
Cardiovasc Qual Outcomes 2011;4:193-7.
4. Taylor LM Jr, Porter JM. Clinical and anatomic considerations for
surgery in femoropopliteal disease and the results of surgery. Circula-
tion 1991;83(2 Suppl):I63-9.
5. Shah DM, Darling RC 3rd, Chang BB, Fitzgerald KM, Paty PS,
Leather RP. Long-term results of in situ saphenous vein bypass.
Analysis of 2058 cases. Ann Surg 1995;222:438-46; discussion: 446–8.
6. Conte MS, Belkin M, Upchurch GR, Mannick JA, Whittemore AD,
Donaldson MC. Impact of increasing comorbidity on infrainguinal
reconstruction: a 20-year perspective. Ann Surg 2001;233:445-52.
7. Berceli SA, Hevelone ND, Lipsitz SR, Bandyk DF, Clowes AW,
Moneta GL, et al. Surgical and endovascular revision of infrainguinal
vein bypass grafts: analysis of midterm outcomes from the PREVENT
III trial. J Vas Surg 2007;46:1173-9.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 5 Conte et al 11858. Nguyen LL, Conte MS, Menard MT, Gravereaux EC, Chew DK,
Donaldson MC, et al. Infrainguinal vein bypass graft revision: factors
affecting long-term outcome. J Vasc Surg 2004;40:916-23.
9. Owens CD. Adaptive changes in autogenous vein grafts for
arterial reconstruction: clinical implications. J Vasc Surg 2010;51:
736-46.
10. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG.
Expression of cyclin-dependent kinase inhibitors in vascular disease.
Circ Res 1998;82:396-403.
11. Nabel EG. CDKs and CKIs: Molecular targets for tissue remodelling.
Nat Rev Drug Discov 2002;1:587-98.
12. Chen D, Krasinski K, Sylvester A, Chen J, Nisen PD, Andres V.
Downregulation of cyclin-dependent kinase 2 activity and cyclin A
promoter activity in vascular smooth muscle cells by p27(KIP1), an
inhibitor of neointima formation in the rat carotid artery. J Clin Invest
1997;99:2334-41.
13. Tanner FC, Boehm M, Akyurek LM, San H, Yang ZY, Tashiro J, et al.
Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1),
p21(Cip1), and p16(Ink4) on vascular smooth muscle cell prolifera-
tion. Circulation 2000;101:2022-5.
14. Sedding DG, Seay U, Fink L, Owens CD, Ridker PM, Belkin M, et al.
Mechanosensitive p27Kip1 regulation and cell cycle entry in vascular
smooth muscle cells. Circulation 2003;108:616-22.
15. Gonzalez P, Diez-Juan A, Coto E, Alvarez V, Reguero JR, Batalla A,
Andrés V, et al. A single-nucleotide polymorphism in the human
p27kip1 gene (-838C>A) affects basal promoter activity and the risk of
myocardial infarction. BMC Biol 2004;2:5.
16. van Tiel CM, Bonta PI, Rittersma SZ, Beijk MA, Bradley EJ,
Klous AM, et al. p27kip1-838C>A single nucleotide polymorphism is
associated with restenosis risk after coronary stenting and modulates
p27kip1 promoter activity. Circulation 2009;120:669-76.
17. Owens CD, Ridker PM, Belkin M, Hamdan AD, Pomposelli F,
Logerfo F, et al. Elevated C-reactive protein levels are associated with
postoperative events in patients undergoing lower extremity vein bypass
surgery. J Vasc Surg 2007;45:2-9; discussion: 9.
18. Owens CD, Rybicki FJ, Wake N, Schanzer A, Mitsouras D, Gerhard-
Herman MD, et al. Early remodeling of lower extremity vein grafts:
inﬂammation inﬂuences biomechanical adaptation. J Vasc Surg
2008;47:1235-42.
19. Kenagy RD, Fukai N, Min SK, Jalikis F, Kohler TR, Clowes AW.
Proliferative capacity of vein graft smooth muscle cells and ﬁbro-
blasts in vitro correlates with graft stenosis. J Vasc Surg 2009;49:
1282-8.
20. Moreno K, Murray-Wijelath J, Yagi M, Kohler T, Hatsukami T,
Clowes A, et al. Circulating inﬂammatory cells are associated with vein
graft stenosis. J Vasc Surg 2011;54:1124-30.21. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S,
et al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
22. Diez-Juan A, Castro C, Edo MD, Andres V. Role of the growth
suppressor p27Kip1 during vascular remodeling. Curr Vasc Pharmacol
2003;1:99-106.
23. Boehm M, Olive M, True AL, Crook MF, San H, Qu X, et al. Bone
marrow-derived immune cells regulate vascular disease through
a p27(Kip1)-dependent mechanism. J Clin Invest 2004;114:419-26.
24. Chen HL, Liu K, Meng XY, Wen XD, You QS. Local application of
rapamycin inhibits vein graft restenosis in rabbits. Transplant Proc
2011;43:2017-21.
25. Owens CD, Ho KJ, Conte MS. Lower extremity vein graft failure:
a translational approach. Vasc Med 2008;13:63-74.
26. Gasper WJ, Owens CD, Kim JM, Hills N, Belkin M, Creager MA, et al.
Early (30-day) vein remodeling is predictive of mid-term graft patency
following lower extremity bypass. J Vasc Surg 2012; in press [doi:10.
1016/j.jvs.2012.06.098].
27. Alexander JH, Haﬂey G, Harrington RA, Peterson ED,
Ferguson TB Jr, Lorenz TJ, et al. Efﬁcacy and safety of edifoligide, an
E2F transcription factor decoy, for prevention of vein graft failure
following coronary artery bypass graft surgery: PREVENT IV:
a randomized controlled trial. JAMA 2005;294:2446-54.
28. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ,
et al. Results of PREVENT III: a multicenter, randomized trial of
edifoligide for the prevention of vein graft failure in lower extremity
bypass surgery. J Vasc Surg 2006;43:742-51; discussion: 751.
29. Ellis SG, Chen MS, Jia G, Luke M, Cassano J, Lytle B. Relation of
polymorphisms in ﬁve genes to long-term aortocoronary saphenous
vein graft patency. Am J Cardiol 2007;99:1087-9.
30. Pereira AC, Miyakawa AA, Lopes NH, Soares PR, de Oliveira SA,
Cesar LA, et al. Dynamic regulation of MTHFR mRNA expression and
C677T genotype modulate mortality in coronary artery disease patients
after revascularization. Thromb Res 2007;121:25-32.
31. Emiroglu O, Durdu S, Egin Y, Akar AR, Alakoc YD, Zaim C, et al.
Thrombotic gene polymorphisms and postoperative outcome after
coronary artery bypass graft surgery. J Cardiothorac Surg 2011;6:120.Submitted Jul 20, 2012; accepted Nov 3, 2012.
Additional material for this article may be found online
at www.jvascsurg.org.
Supplementary Table I (online only). Patient inclusion and exclusion criteria for Seattle cohort
Category Including Excluding
Type of surgical
operation
Elective infrainguinal arterial bypass with
autogenous vein for claudication or critical
limb ischemia due to chronic atherosclerotic
occlusive disease. Simultaneous endovascular
inﬂow procedures permitted.
Operations for nonatherosclerotic, or aneurysmal
disease. Simultaneous femoralefemoral, or
aortobifemoral bypass. Post-op graft thrombosis
for technical reasons, within the ﬁrst 30 days.
Conduit Autogenous vein graft >15 cm, including
high-risk vein graftsa (single or spliced non-GSV
segments, vein diameter <3 mm, surgical revisions
or corrections performed at index operation).
Composite grafts that include prosthetic conduits.
Thrombectomy and/or revision of an existing graft.
Systemic conditions Stable malignancy (eg, prostate cancer)a
Diabetes mellitusa
Smokinga
Hyperlipidemiaa
Statin therapya
Any type of antithrombotic therapya
Renal impairment (if BUN <60 mg/dL)a
Previously failed leg bypassa
Actively progressive malignancy
Chemotherapy for malignancy (#3 months)
Renal failure (dialysis)
Systemic inﬂammatory disease (eg, lupus)
Invasive infection
A diagnosed hypercoagulable state
Patient characteristics Agea: >18 years; racea: all races Agea: <18 years
Administrative Already enrolled in an investigational drug study.
Previously enrolled in this study.
Can’t follow-up, expected survival <6 months.
BUN, Blood urea nitrogen; GSV, great saphenous vein.
aThese conditions are identiﬁed as prospective covariables.
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1185.e1 Conte et al May 2013Supplementary Table II (online only). Characteristics
of Seattle cohort by p27 Kip1-838 genotype
Variablea -838AA -838CA -838CC
Patients 6 (11.5) 34 (65.4) 12 (23.1)
Age, years 69.3 6 12.6 65.4 6 7.9 63.8 6 6.8
Male sex 5 (83.3) 31 (91.2) 12 (100.0)
Caucasian race 6 (100) 34 (100) 11 (92)
CLI 6 (100) 19 (56) 7 (58)
Diabetes mellitus 4 (67) 14 (41) 2 (17)
CAD/CVD 1 (17) 13 (38) 4 (33)
Current tobacco 2 (33) 16 (47) 7 (58)
Tissue loss 2 (33) 14 (41) 3 (25)
Infrapopliteal target 2 (33) 8 (24) 0 (0)
CAD, Coronary artery disease; CLI, critical limb ischemia; CVD, cerebro-
vascular disease.
aContinuous data are shown as mean 6 standard deviation and categoric
data as number (%).Supplementary Table III (online only). Summary of
clinical outcomes in Seattle cohort by p27 Kip1-838
genotype
Outcome
AA,
No. (%)
CA,
No. (%)
CC,
No. (%)
Total,
No. (%)
Loss of primary patency 1 (17) 15 (44) 3 (25) 19 (37)
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Supplementary Fig (online only). Effect of the p27 kip1-838C>A
polymorphism on p27Kip1 promoter activity in human venous
ﬁbroblasts. Primary cultured adventitial ﬁbroblasts from human
saphenous vein (Kenagy et al J Vasc Surgery 2009; 49:1282-8)
were transfected by electroporation with the indicated p27Kip1
promoter-luciferase constructs used by van Tiel et al (Circulation
2009; 120:669-676) containing the -838A or -838C variant. One
day after transfection, cells were changed to serum-free medium for
24 hours and ﬁreﬂy luciferase activity measured. Luciferase activity
was normalized to Renilla luciferase and expressed as fold of the
empty pGL3 shuttle vector. Data shown are mean of four inde-
pendent experiments (P < .006 by paired t-test).
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